ALK inhibitors have become the standard therapeutic option for advanced ALK-positive NSCLC.10 Crizotinib, a first-generation ALK inhibitor, showed a response rate close to 75% and a median progression-free survival (PFS) of nearly 12 months. Here, ALK is linked to non-small cell lung carcinoma.